Objective: To evaluate the anti-platelet aggregation activities of the Chinese patent medicines (CPM) for promoting blood circulation and removing blood stasis

explore the medication rules

and provide certain experimental basis for the development of anti platelet drugs. Method: High-throughput microwell turbidimetric method was used to detect drug response to platelet aggregation induced by adenosine diphosphate (ADP) and thrombin. Result: The 41 kinds of tested Chinese patent medicines (CPM) showed antagonistic effect in different degrees (inhibitory rate of 30%~98%) on platelet aggregation induced by ADP or thrombin. 18 kinds of CPM among them showed selectivity for the inducers. Formulation analysis revealed that highest anti-platelet aggregation activities were demonstrated by the CPM containing ingredients of Salviae Miltiorrhizae Radix et Rhizoma

Chuanxiong Rhizoma

Carthami Flos

Notoginseng Radix et Rhizoma

and Borneolum Syntheticum. Furthermore

the CPMs with promoting blood circulation character were more frequently combined with those of multi-tonic medicine

resuscitation medicine and hemostatic medicine to achieve more potent inhibitory effects on platelet aggregation. Conclusion: The compound CPMs for promoting blood circulation and removing blood stasis can achieve anti-platelet aggregation activity by anti-ADP and antithrombin means. The medicines with ‘Qi-regulating’

‘Qi-tonifying’ and ‘resuscitation’ efficacy may strengthen the activity of anti-platelet aggregation.